Physician profile
Bryan L Kimura
NPI 1710547534
$13,490.71
in general payments reported to CMS, 2019-2025
23 companies · $1,458 in 2025
The $1,458 reported for 2025 was more than what 95% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $157 · 2020: $1,096 · 2021: $2,214 · 2022: $3,180 · 2023: $3,618 · 2024: $1,768 · 2025: $1,458.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,818 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,000 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,818.31 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,000.00 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $4,750.17 | 2022-2025 | Lotemax, Vyzulta, Zenlens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $2,520.02 | 2019-2021 | |
| Notal Vision, INC. | $791.39 | 2022 | |
| Alcon Vision LLC | $710.83 | 2020-2025 | Tryptyr |
| Johnson & Johnson Vision Care, INC. | $648.65 | 2020-2025 | Acuvue |
| Oyster Point Pharma, INC. | $641.19 | 2022-2023 | Tyrvaya |
| Sun Pharmaceutical Industries INC. | $621.91 | 2022-2025 | Cequa |
| Allergan, INC. | $493.73 | 2021-2022 | |
| Biotissue Holdings INC. | $335.30 | 2023 | |
| Tarsus Pharmaceuticals, INC. | $246.14 | 2024-2025 | Xdemvy |
| Astellas Pharma US INC | $243.96 | 2024 | Izervay |
| Aerie Pharmaceuticals, INC. | $239.01 | 2021 | |
| Abbvie INC. | $218.27 | 2022-2025 | |
| Sight Sciences, INC. | $148.43 | 2022 | |
| Mallinckrodt Hospital Products INC. | $146.18 | 2024 | Acthar |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $129.85 | 2021-2022 | |
| Apellis Pharmaceuticals, INC. | $125.00 | 2024 | Syfovre |
| Horizon Therapeutics Plc | $125.00 | 2023 | Tepezza |
| Dompe US, INC. | $124.75 | 2023 | Oxervate |
| Optos, INC. | $101.65 | 2022 | |
| Carl Zeiss Meditec, INC. | $86.67 | 2019 | |
| Rxsight INC | $25.59 | 2023 | Rxsight Injector Cartridge, Rxsight Light Adjustable Lens (Rxlal), Rxsight Contact Lens |
| Coopervision INC. | $17.02 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Kimura listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.